With an increasing number of biologics to treat moderate-to-severe psoriasis, selection of the right drug becomes a real challenge for every dermatologist. Therapy should be guided by comorbidities but also by individual patient preferences. Novel drugs are not only more effective but also safer than conventional immunosuppressive drugs.
At present, there are numerous treatment possibilities for psoriasis. But does one choose the right agent? Selection of therapy has to take comorbidities into account. “The first question, I ask my patients is, do you have joint pain?” said Prof. Mark Lebwohl (Mount Sinai School of Medicine, USA) . All tumour necrosis factor alpha (TNF-α) blockers are also effective in psoriatic arthritis (PsA). Other treatment possibilities are ustekinumab, apremilast, and the IL-17 blockers secukinumab, ixekizumab, and brodalumab.
Higher risk of non-melanoma skin cancer with TNF-alpha blockers
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Should we use more hormonal therapy? Next Article
Can JAK inhibitors close the current therapeutic gap in AD? »
Table of Contents: AAD 2019
Atopic Dermatitis: Many New Therapies in the Pipeline
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
What's New and Hot in Acne
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.